A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

September 4, 2025

Study Completion Date

September 4, 2025

Conditions

Hepatic Impairment

Interventions

DRUG

AZD2389

Single oral dose of AZD2389 in participants from all cohorts

Trial Locations (5)

Research Site, Orlando

Research Site, Miami Lakes

Research Site, San Antonio

Research Site, Chandler

Research Site, Rialto